[go: up one dir, main page]

DK245287D0 - Peptider relateret til htlv-iii virus, antistoffer mod disse peptider, vacciner til aktiv og passiv immunisering mod aids-virus og fremgangsmaade og udstyr til serologisk paavisning af aids virus - Google Patents

Peptider relateret til htlv-iii virus, antistoffer mod disse peptider, vacciner til aktiv og passiv immunisering mod aids-virus og fremgangsmaade og udstyr til serologisk paavisning af aids virus

Info

Publication number
DK245287D0
DK245287D0 DK245287A DK245287A DK245287D0 DK 245287 D0 DK245287 D0 DK 245287D0 DK 245287 A DK245287 A DK 245287A DK 245287 A DK245287 A DK 245287A DK 245287 D0 DK245287 D0 DK 245287D0
Authority
DK
Denmark
Prior art keywords
aids
viruses
htlv
iii
alpha
Prior art date
Application number
DK245287A
Other languages
English (en)
Other versions
DK173040B1 (da
DK245287A (da
Inventor
Allan L Goldstein
Su Sun Wang
Original Assignee
Viral Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viral Technologies Inc filed Critical Viral Technologies Inc
Publication of DK245287D0 publication Critical patent/DK245287D0/da
Publication of DK245287A publication Critical patent/DK245287A/da
Application granted granted Critical
Publication of DK173040B1 publication Critical patent/DK173040B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C07K16/1143—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK198702452A 1986-05-19 1987-05-14 Peptider relateret til HIV, antigener omfattende peptiderne, antistoffermod disse peptider, vacciner og antisera til aktiv DK173040B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86459986A 1986-05-19 1986-05-19
US86459986 1986-05-19

Publications (3)

Publication Number Publication Date
DK245287D0 true DK245287D0 (da) 1987-05-14
DK245287A DK245287A (da) 1987-11-20
DK173040B1 DK173040B1 (da) 1999-11-29

Family

ID=25343634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198702452A DK173040B1 (da) 1986-05-19 1987-05-14 Peptider relateret til HIV, antigener omfattende peptiderne, antistoffermod disse peptider, vacciner og antisera til aktiv

Country Status (17)

Country Link
EP (1) EP0246829B1 (da)
JP (3) JPH089636B2 (da)
KR (1) KR910002690B1 (da)
CN (1) CN87103568A (da)
AT (1) ATE100469T1 (da)
AU (1) AU606595B2 (da)
DE (1) DE3788822T2 (da)
DK (1) DK173040B1 (da)
ES (1) ES2061495T3 (da)
GB (1) GB2190679B (da)
IE (1) IE60274B1 (da)
IL (1) IL82471A (da)
IN (1) IN167198B (da)
MX (1) MX167236B (da)
NZ (1) NZ220200A (da)
PH (1) PH26239A (da)
ZA (1) ZA873215B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
EP0346022B1 (en) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptide fragments of HIV
US5219725A (en) 1988-12-05 1993-06-15 Idexx Laboratories Incorporated Monoclonal antibodies to feline-t-lymphotropic lentivirus
DE69008712T2 (de) * 1989-02-01 1994-10-13 Du Pont Hiv p17-test für die überwachung des verlaufs von aids.
EP0471752A4 (en) * 1989-05-08 1992-09-02 Idexx Corp. Polypeptides of feline t-cell lymphotropic lentivirus
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
DE4106686A1 (de) * 1991-03-02 1992-09-03 Daimler Benz Ag Verriegelungsanordnung
FR2734281B1 (fr) * 1995-05-18 1997-07-25 Commissariat Energie Atomique Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1
EP0969864A1 (en) 1996-08-09 2000-01-12 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
DE60045249D1 (de) 2000-12-21 2010-12-30 Semiconductor Components Ind Verfahren und Vorrichtung zur Reduktion von Schaltgeräuschen in einem Transformator eines Schaltnetzteils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264571A (en) * 1979-01-22 1981-04-28 George Washington University Radioimmunoassay of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4339427A (en) * 1980-04-14 1982-07-13 Hoffmann-La Roche Inc. Radioimmunoassay of thymosinα
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
US4517119A (en) * 1983-04-04 1985-05-14 Hoffmann-La Roche Inc. Synthesis of thymosin α1

Also Published As

Publication number Publication date
EP0246829B1 (en) 1994-01-19
ES2061495T3 (es) 1994-12-16
JP2598245B2 (ja) 1997-04-09
DE3788822T2 (de) 1994-07-28
JPH089636B2 (ja) 1996-01-31
GB2190679B (en) 1991-02-20
JPH083200A (ja) 1996-01-09
MX167236B (es) 1993-03-11
CN87103568A (zh) 1988-01-27
EP0246829A2 (en) 1987-11-25
AU606595B2 (en) 1991-02-14
DK173040B1 (da) 1999-11-29
DK245287A (da) 1987-11-20
JPH0925300A (ja) 1997-01-28
PH26239A (en) 1992-04-01
DE3788822D1 (de) 1994-03-03
IE871289L (en) 1987-11-19
ATE100469T1 (de) 1994-02-15
AU7313587A (en) 1987-11-26
IN167198B (da) 1990-09-15
KR910002690B1 (ko) 1991-05-03
EP0246829A3 (en) 1989-08-09
KR870011154A (ko) 1987-12-21
GB8711567D0 (en) 1987-06-17
GB2190679A (en) 1987-11-25
IL82471A0 (en) 1987-11-30
IE60274B1 (en) 1994-06-29
ZA873215B (en) 1987-10-28
IL82471A (en) 1993-02-21
JPS6327498A (ja) 1988-02-05
NZ220200A (en) 1990-08-28

Similar Documents

Publication Publication Date Title
Schable et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections
Jiang et al. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.
Arthur et al. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120
Nara et al. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses
Rusche et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
Albert et al. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB
CA1280363C (en) Peptide composition and method for the detection of antibodies to htlv-iii
DK245287A (da) Peptider relateret til htlv-iii virus, antistoffer mod disse peptider, vacciner til aktiv og passiv immunisering mod aids-virus og fremgangsmaade og udstyr til serologisk paavisning af aids virus
PT90376B (pt) Processo para a preparacao de peptidos env-codificados de hiv capazes de elicitarem anticorpos que inibem hiv em mamiferos e de anticorpos monoclonais que inibem hiv mediante utilizacao desses peptidos
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
DK0661999T3 (da) Vacciner mod felint immundefekt virus (FIV)
Haynes et al. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
FI101797B (fi) STLV-III-virukseen liittyvät polypeptidit, diagnostiset järjestelmät j a määritysmenetelmät
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Fischinger et al. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I,-II,-III)
Böttiger et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
Krook et al. HTLV-II among injecting drug users in Stockholm
Zandomeni et al. The trans-activating C-type retroviruses share a distinct epitope (s) that induces antibodies in certain infected hosts
Peeters et al. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions
Benjouad et al. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160
US4943627A (en) Peptides involved in the pathogenesis of HIV infection
DK0426314T3 (da) HIV-relaterede peptider

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed